2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Melanoma
3
Neoplasms
2
HIV Infections
2
Carcinoma, Hepatocellular
2
Acquired Immunodeficiency Syndrome
2
Stomach Ulcer
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sarcoma, Kaposi
1
Sarcoma
1
Muscle Neoplasms
1
Hepatitis B
1
Duodenal Ulcer
1
Adenoviridae Infections
1
AIDS-Related Complex
1
Interventions
atezolizumab
2
Gemcitabine
2
Cell Count
2
ziprasidone
1
valrubicin
1
tretazicar
1
pembrolizumab
1
liposomal doxorubicin
1
fludarabine phosphate
1
fludarabine
1
enadenotucirev
1
Zolpidem
1
Warfarin
1
Vecuronium Bromide
1
Vancomycin
1
Vaccines
1
Tumor Necrosis Factor-alpha
1
Tranexamic Acid
1
Tobramycin
1
Spironolactone
1
Sevelamer
1
Rocuronium
1
Radiotherapy
1
Piperacillin, Tazobactam Drug Combination
1
Pentobarbital
1
Oxycodone
1
Oncolytic Virotherapy
1
Nifedipine
1
Nafcillin
1
Molindone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenoviridae Infections
×
Tumor Necrosis Factor-alpha
×
Clear all
NCT04695327
2026-03-06
TUNIMO
TILT Biotherapeutics Ltd.
Phase 1
Completed
32 enrolled